Primary Tumor Resection for Stage IV Non-small-cell Lung Cancer Without Progression After First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Treatment: A Retrospective Case-Control Study
Journal
Annals of surgical oncology
Journal Volume
29
Journal Issue
8
Pages
4873
Date Issued
2022-08
Author(s)
Abstract
In studies of stage IV epidermal growth factor receptor (EGFR)-mutant nonsmall-cell lung cancer (NSCLC), <10% of patients underwent surgery; thus, the effect of surgery in these patients remains unclear. We investigated whether primary lung tumor resection could improve the survival of patients with stage IV EGFR-mutant NSCLC without progression after first-line EGFR-tyrosine kinase inhibitor (EGFR-TKI) treatment.
Subjects
OPEN-LABEL; MAINTENANCE THERAPY; ABLATIVE THERAPY; SYSTEMIC THERAPY; EGFR MUTATIONS; ASIAN PATIENTS; ERLOTINIB; CHEMOTHERAPY; MULTICENTER; ADENOCARCINOMA
SDGs
Publisher
SPRINGER
Type
journal article